Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 2, 2021

ICR scientists say new blood test can help guide breast cancer treatment

The test can be used to guide and adjust treatment for patients with advanced breast cancer.

A new study by scientists at The Institute of Cancer Research (ICR), London, and The Royal Marsden NHS Foundation Trust has found that a simple blood test is capable of detecting specific genetic mutations in breast tumours and helping to guide treatment for patients.

The blood test will provide clinicians with a better knowledge of the genetic characteristics of individual breast cancers.

It can also be used to guide and adjust treatment for breast cancer patients without the need for invasive and risky tissue biopsies.

By using the test to analyse tumour DNA traces circulating in the blood, researchers can identify mutations that influence cancer growth and provide resistance to treatment.

The scientists evaluated tumour DNA from blood tests obtained from a total of 800 advanced breast cancer patients in a multiple parallel cohort, open-label, multicentre plasmaMATCH trial.

They tried to identify targetable defects in genes such as BRAF, HER2 and PIK3CA, which are connected to breast cancer.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

Furthermore, the scientists were able to identify the patients who were most likely to have genetic changes in their breast tumours by analysing their tumour DNA with the help of liquid biopsies.

Several new potential therapeutic approaches to treat advanced breast cancer were also identified.

ICR molecular oncology professor and Royal Marsden Ralph Lauren Centre for Breast Cancer Research head Nick Turner said: “Our latest plasmaMATCH results identify which genetic alterations are common and most likely to drive breast cancer in different groups of patients while also shedding light on the processes influencing the development of resistance to treatments.

“We have identified the mutations that breast cancer can acquire to evolve through treatment, helping to advance our understanding of how cancers become resistant to treatment.

“This will allow us, in the future, to come up with new strategies to tackle resistance, aiming to improve outcomes for women living with advanced breast cancer.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU